{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.9","value":"20.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"Cycle 1 - day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.4","value":"19.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Cycle 1 - day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The terminal half-life (t1/2) of the AFM13. Geometric coefficient of variation is given in percentages.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The pharmacokinetic set (PK) consists of subjects who had at least received one dose of study drug and had at least one post dose PK measurement.","reportingStatus":"POSTED","timeFrame":"Predose and 1 hour after start of infusion, end of injection (EOI) and 1 hour, 2 hours, 3 hours, 24 hours and 48 hours after EOI on Cycle 1 Day 1 and Day 29.","title":"The Terminal Half-life (t1/2) of AFM13","type":"SECONDARY","unitOfMeasure":"hour"}